Journal
CLINICAL RHEUMATOLOGY
Volume 29, Issue 6, Pages 677-681Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s10067-010-1410-x
Keywords
Anti-tumor necrosis factor-alpha; Biologics; Infections; Juvenile idiopathic arthritis
Categories
Ask authors/readers for more resources
Anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents are widely used to treat children with juvenile idiopathic arthritis (JIA) whose disease is resistant to conventional therapy. Although generally well tolerated, use of these agents has been associated with an increased risk of infection. In particular, in patients treated with anti-TNF-alpha agents, there is an increased susceptibility to infection by intracellular organisms such as tuberculosis, and common infections may present atypically or be more severe. We report four cases of serious musculoskeletal infections among 31 children with JIA being treated with anti-TNF-alpha agents, two of which were secondary to group A beta-hemolytic Streptococcus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available